Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5
about
Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5Parenteral oestrogen in the treatment of prostate cancer: a systematic reviewTiming and choice of androgen ablation.Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09).Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases.Clinical presentation and predictors of survival related to extent of bone metastasis in 900 prostate cancer patients.Transdermal estradiol in castrate and chemotherapy resistant prostate cancerQuality of life in patients with skeletal metastases of prostate cancer and status prior to start of endocrine therapy: results from the Scandinavian Prostate Cancer Group Study 5.Cardiovascular complications in patients with advanced prostatic cancer treated by means of orchiectomy or polyestradiol phosphate.Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer.A high pretreatment plasma oestradiol level is associated with a low risk of acute myocardial infarction in parenteral oestrogen therapy for locally advanced prostate cancer.Changes in vascular flow after transdermal oestradiol therapy for prostate cancer: a mechanism for cardiovascular toxicity and benefit?Clinical characteristics and quality-of-life in patients surviving a decade of prostate cancer with bone metastases.
P2860
Q28277569-DAA4A1A1-D81C-4941-95D3-AF0AE1975D20Q34749291-47A75137-C9D0-4DC0-BB5F-17CF13A15A7AQ35847645-65B7552D-82D0-4931-9E22-B4D8EB720FA7Q36751550-A08AC42B-348E-42D2-987D-94F684D18549Q39222023-B1D2A98D-0E41-4709-B145-252A61D946B5Q40591427-59667B82-8175-4ECF-9A84-1C17076FDE39Q42082713-5B24E397-8842-45DD-BE19-0BE51B2ECD0AQ46374910-3147A422-A251-4EAA-9483-4B5F02D4609DQ46784756-EFE55760-F8F6-4CB9-A12E-3E6A29DA8D6DQ46813482-F8442E7E-BEC5-40A7-BE39-3D05059EDD7FQ46857561-E116AD54-D7C3-4C5E-B3CB-5390B8710DB4Q46936650-A4D2EB6B-79F5-4A03-B94B-99C17C5CD680Q48037073-0BA7087D-50E2-4D6F-A935-7DF4D60B42AC
P2860
Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5
description
2002 nî lūn-bûn
@nan
2002 թուականին հրատարակուած գիտական յօդուած
@hyw
2002 թվականին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Parenteral estrogen versus com ...... ancer Group (SPCG) Study No. 5
@ast
Parenteral estrogen versus com ...... ancer Group (SPCG) Study No. 5
@en
Parenteral estrogen versus com ...... ancer Group (SPCG) Study No. 5
@nl
type
label
Parenteral estrogen versus com ...... ancer Group (SPCG) Study No. 5
@ast
Parenteral estrogen versus com ...... ancer Group (SPCG) Study No. 5
@en
Parenteral estrogen versus com ...... ancer Group (SPCG) Study No. 5
@nl
prefLabel
Parenteral estrogen versus com ...... ancer Group (SPCG) Study No. 5
@ast
Parenteral estrogen versus com ...... ancer Group (SPCG) Study No. 5
@en
Parenteral estrogen versus com ...... ancer Group (SPCG) Study No. 5
@nl
P2093
P2860
P1476
Parenteral estrogen versus com ...... ancer Group (SPCG) Study No. 5
@en
P2093
Ake Pousette
Eberhard Varenhorst
Einar Brekkan
Finn Rasmussen
Inger Hagerman
Jaakko Salo
Jan Erik Damber
Lena Damber
Martti Ala-Opas
Per Olov Hedlund
P2860
P304
P356
10.1080/003655902762467549
P407
P577
2002-01-01T00:00:00Z